Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Kallirhoe Kalinderi, Vasileios Papaliagkas, Liana Fidani
Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut-brain axis. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD published in the English language with no time restrictions...
March 29, 2024: International Journal of Molecular Sciences
#22
REVIEW
Michael Khalil, Charlotte E Teunissen, Sylvain Lehmann, Markus Otto, Fredrik Piehl, Tjalf Ziemssen, Stefan Bittner, Maria Pia Sormani, Thomas Gattringer, Samir Abu-Rumeileh, Simon Thebault, Ahmed Abdelhak, Ari Green, Pascal Benkert, Ludwig Kappos, Manuel Comabella, Hayrettin Tumani, Mark S Freedman, Axel Petzold, Kaj Blennow, Henrik Zetterberg, David Leppert, Jens Kuhle
Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice. Potential applications include assessment of disease activity, monitoring of treatment responses, and determining prognosis in many acute and chronic neurological disorders as well as their use as an outcome measure in trials of novel therapies...
April 12, 2024: Nature Reviews. Neurology
#23
REVIEW
Amy Morton, Holly Fraser, Chloe Green, Aaron Drovandi
INTRODUCTION: Balance dysfunction is a debilitating feature of advanced Parkinson's disease (PD), potentially improved by deep brain stimulation (DBS). This systematic review and meta-analysis pooled evidence from randomized controlled trials (RCT) on DBS effectiveness in improving balance in PD. METHODS: A systematic search was conducted to identify eligible RCTs investigating the effectiveness of DBS on improving balance in people with PD. Meta-analysis was performed using random effects models and reported as mean difference and 95% confidence intervals...
April 10, 2024: World Neurosurgery
#24
JOURNAL ARTICLE
Masahiko Hara, Yuichiro Murakawa, Tomomi Wagatsuma, Keito Shinmoto, Masatake Tamaki
This feasibility study enrolled 20 patients with advanced severe Parkinson's disease (PD) to evaluate somato-cognitive coordination therapy (SCCT) using virtual reality. Focusing on the safety and tolerability of SCCT, 17 patients (76±9 years old and 64.7% male) completed the 3-month trial. Key observations included absence of adverse events and tolerability of the participants to SCCT despite initial apprehensions and minor adjustments in medication. Physical functions showed no significant deterioration, suggesting the safety of SCCT...
April 11, 2024: Journal of Parkinson's Disease
#25
JOURNAL ARTICLE
Thyago R Cardim-Pires, Aurélie de Rus Jacquet, Francesca Cicchetti
Our limited understanding of complex neurodegenerative disorders has held us back on the development of efficient therapies. While several approaches are currently being considered, it is still unclear what will be most successful. Among the latest and more novel ideas, the concept of blood or plasma transfusion from young healthy donors to diseased patients is gaining momentum and attracting attention beyond the scientific arena. While young or healthy blood is enriched with protective and restorative components, blood from older subjects may accumulate neurotoxic agents or be impoverished of beneficial factors...
April 12, 2024: Journal of Neurology
#26
REVIEW
Vivek P Chavda, Amit Z Chaudhari, Pankti C Balar, Amol Gholap, Lalitkumar K Vora
Phytoestrogens, also known as xenoestrogens, are secondary metabolites derived from plants that have similar structures and biological effects as human estrogens. These compounds do not directly affect biological functions but can act as agonists or antagonists depending on the level of endogenous estrogen in the body. Phytoestrogens may have an epigenetic mechanism of action independent of estrogen receptors. These compounds are found in more than 300 plant species and are synthesized through the phenylpropanoid pathway, with specific enzymes leading to various chemical structures...
April 11, 2024: Phytotherapy Research: PTR
#27
Gaurav Deepak Patel, Lichao Liu, Ailian Li, Yun-Hsuan Yang, Chia-Chi Shen, Beate Brand-Saberi, Xuesong Yang
BACKGROUND: Millions of people across the globe are affected by conditions like Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI), and Traumatic Brain Injury (TBI), although most occurrences are common in the elderly population. This systematic review aims to highlight the safety of the procedures, their tolerability, and efficacy of the available therapies conducted over the years using mesenchymal stem cells (MSCs) in treating the neurological conditions mentioned above...
2024: Frontiers in Medicine
#28
JOURNAL ARTICLE
Sidney T Baudendistel, Jason R Franz, Abigail C Schmitt, Francesca E Wade, Marc C Pappas, Ka Loong Kelvin Au, Chris J Hass
Persons with Parkinson's disease experience gait alterations, such as reduced step length. Gait dysfunction is a significant research priority as the current treatments targeting gait impairment are limited. This study aimed to investigate the effects of visual biofeedback on propulsive force during treadmill walking in persons with Parkinson's. Sixteen ambulatory persons with Parkinson's participated in the study. They received real-time biofeedback of anterior ground reaction force during treadmill walking at a constant speed...
April 3, 2024: Journal of Biomechanics
#29
RANDOMIZED CONTROLLED TRIAL
Wassilios G Meissner, Philippe Remy, Caroline Giordana, David Maltête, Pascal Derkinderen, Jean-Luc Houéto, Mathieu Anheim, Isabelle Benatru, Thomas Boraud, Christine Brefel-Courbon, Nicolas Carrière, Hélène Catala, Olivier Colin, Jean-Christophe Corvol, Philippe Damier, Estelle Dellapina, David Devos, Sophie Drapier, Margherita Fabbri, Vanessa Ferrier, Alexandra Foubert-Samier, Solène Frismand-Kryloff, Aurore Georget, Christine Germain, Stéphane Grimaldi, Clémence Hardy, Lucie Hopes, Pierre Krystkowiak, Brice Laurens, Romain Lefaucheur, Louise-Laure Mariani, Ana Marques, Claire Marse, Fabienne Ory-Magne, Vincent Rigalleau, Hayet Salhi, Amandine Saubion, Simon R W Stott, Claire Thalamas, Claire Thiriez, Mélissa Tir, Richard K Wyse, Antoine Benard, Olivier Rascol
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period...
April 4, 2024: New England Journal of Medicine
#30
JOURNAL ARTICLE
Mairéad Doherty, Emeka Chukwusa, Regina McQuillan, Faith Cranfield, Wei Gao
Background: Long-term neurological conditions include multiple sclerosis, Parkinson's-related diseases, and motor neurone disease. National and international guidelines recommend a palliative approach for advancing neurological disease, but there is little research describing and comparing the palliative care needs of these patients side by side. Objective: The aim of this study was to describe and compare the symptom burden and psychological distress of patients with multiple sclerosis, Parkinson's-related diseases, and motor neurone disease...
April 9, 2024: Journal of Palliative Medicine
#31
JOURNAL ARTICLE
Dalia Majumdar, Diane Webb, Stephanie Parsons, Elizabeth M Selwan-Lewis, Trisha Rettig, Emily Chastain, Winifred Obanor, Rob Birnberg, Amy Kuang
OBJECTIVE: Effective health communication is critical for understanding and acting on health information. This cross-sectional study explored participants' understanding of their health condition, their preferences for receiving health communications, and their interest in receiving clinical trial results across several therapeutic areas. METHODS: The study recruited participants via social media, email newsletters, and advocacy organizations. An online screener captured demographic information (health conditions, age, race/ethnicity, gender, and education)...
April 10, 2024: Current Medical Research and Opinion
#32
JOURNAL ARTICLE
Jee-Young Lee, Hyeo-Il Ma, Joaquim J Ferreira, José-Francisco Rocha, Young Hee Sung, In-Uk Song, Tae-Beom Ahn, Do Young Kwon, Sang-Myung Cheon, Jong-Min Kim, Chong Sik Lee, Phil Hyu Lee, Jeong-Ho Park, Jae-Hyeok Lee, Mee Young Park, Sang Jin Kim, Jong Sam Baik, Seong-Min Choi, Hae-Won Shin, Ho-Won Lee, Suk Yun Kang, Beomseok Jeon
BACKGROUND: Increasing levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol-O-methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing-off symptoms in Parkinson's disease (PD) patients. OBJECTIVES: To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing-off in PD patients. METHODS: ADOPTION was a randomized, parallel-group, open-label, Phase 4 study conducted in Korea...
April 9, 2024: Movement Disorders Clinical Practice
#33
JOURNAL ARTICLE
Tanmoy Roy, Swarupanjali Padhi, Rupa Mazumder, Chandana Majee, Saumya Das, Monika Monika, Rashmi Mishra, Bhupinder Kapoor
Neurodegenerative diseases are emerging as a global health concern in the current sce-nario, and their association with mitochondrial defects has been a potential area of research. Mi-tochondria, one of the essential organelles of the cell, serve as the cell's powerhouse, producing energy and ensuring cellular health. Neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, and Pelizaeus-Merzbacher disease have been found to be primarily triggered by mitochondrial malfunction...
April 5, 2024: Current Topics in Medicinal Chemistry
#34
REVIEW
Moritz Ernst, Ann-Kristin Folkerts, Romina Gollan, Emma Lieker, Julia Caro-Valenzuela, Anne Adams, Nora Cryns, Ina Monsef, Antje Dresen, Mandy Roheger, Carsten Eggers, Nicole Skoetz, Elke Kalbe
BACKGROUND: Physical exercise is effective in managing Parkinson's disease (PD), but the relative benefit of different exercise types remains unclear. OBJECTIVES: To compare the effects of different types of physical exercise in adults with PD on the severity of motor signs, quality of life (QoL), and the occurrence of adverse events, and to generate a clinically meaningful treatment ranking using network meta-analyses (NMAs). SEARCH METHODS: An experienced information specialist performed a systematic search for relevant articles in CENTRAL, MEDLINE, Embase, and five other databases to 17 May 2021...
April 8, 2024: Cochrane Database of Systematic Reviews
#35
JOURNAL ARTICLE
Jenny N Guo, Mark A Assmus, Nicholas S Dean, Matthew S Lee, Clarissa Wong, Jordan Rich, Jessica Helon, Mitchell M Huang, Amy E Krambeck
INTRODUCTION: We aimed to compare holmium laser enucleation of the prostate (HoLEP) outcomes in patients with and without neurologic diseases (ND). METHODS: A prospectively maintained database of patients undergoing HoLEP from January 2021 to April 2022 was reviewed. The following NDs were included: diabetes-related neuropathy/neurogenic bladder, Parkinson's disease, dementia, cerebrovascular accident, multiple sclerosis, traumatic brain injury, transient ischemic attack, brain/spinal tumors, myasthenia gravis, spinal cord injury, and other...
April 2, 2024: Canadian Urological Association Journal
#36
REVIEW
Liyan Yao, Yong Yang, Xiaowei Yang, Mohammad J Rezaei
Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, leading to motor and non-motor symptoms. Emerging research has shed light on the role of gut microbiota in the pathogenesis and progression of PD. Nutraceuticals such as curcumin, berberine, phytoestrogens, polyphenols (e.g., resveratrol, EGCG, and fisetin), dietary fibers have been shown to influence gut microbiota composition and function, restoring microbial balance and enhancing the gut-brain axis...
April 8, 2024: Molecular Neurobiology
#37
JOURNAL ARTICLE
Jenny Sedhed, Hanna Johansson, Nina Andersson, Elisabet Åkesson, Elke Kalbe, Erika Franzén, Breiffni Leavy
BACKGROUND: Parkinson's disease (PD) drastically affects motor and cognitive function, but evidence shows that motor-cognitive training improves disease symptoms. Motor-cognitive training in the home is scarcely investigated and eHealth methods can provide continual support for PD self-management. Feasibility testing is however required. OBJECTIVE: To assess the feasibility (i) Recruitment capability (ii) Acceptability and Suitability (iii) Demand and Safety of a home-based motor-cognitive eHealth exercise intervention in PD...
April 5, 2024: BMC Neurology
#38
REVIEW
Benjamin Davidson, Luka Milosevic, Laura Kondrataviciute, Lorraine V Kalia, Suneil K Kalia
Deep Brain Stimulation (DBS) has become a pivotal therapeutic approach for Parkinson's Disease (PD) and various neuropsychiatric conditions, impacting over 200,000 patients. Despite its widespread application, the intricate mechanisms behind DBS remain a subject of ongoing investigation. This article provides an overview of the current knowledge surrounding the local, circuit, and neurobiochemical effects of DBS, focusing on the subthalamic nucleus (STN) as a key target in PD management. The local effects of DBS, once thought to mimic a reversible lesion, now reveal a more nuanced interplay with myelinated axons, neurotransmitter release, and the surrounding microenvironment...
April 4, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
#39
REVIEW
Richard K Wyse, Tom Isaacs, Roger A Barker, Mark R Cookson, Ted M Dawson, David Devos, David T Dexter, Joy Duffen, Howard Federoff, Brian Fiske, Thomas Foltynie, Susan Fox, J Timothy Greenamyre, Karl Kieburtz, Jeffrey H Kordower, Dimitri Krainc, Helen Matthews, Darren J Moore, Leah Mursaleen, Michael A Schwarzschild, Simon R W Stott, David Sulzer, Per Svenningsson, Caroline M Tanner, Camille Carroll, David K Simon, Patrik Brundin
In 2011, the UK medical research charity Cure Parkinson's set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson's disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data...
April 5, 2024: Journal of Parkinson's Disease
#40
JOURNAL ARTICLE
Rodrigo Medina-García, Juan A López-Rodríguez, Cristina María Lozano-Hernández, Verónica Ruiz Bejerano, Paride Criscio, Isabel Del Cura-González
BACKGROUND: Information and communication technologies (ICTs) have been positioned as useful tools to facilitate self-care. The interaction between a patient and technology, known as usability, is particularly important for achieving positive health outcomes. Specific characteristics of patients with chronic diseases, including multimorbidity, can affect their interaction with different technologies. Thus, studying the usability of ICTs in the field of multimorbidity has become a key element to ensure their relevant role in promoting self-care...
April 5, 2024: JMIR Human Factors
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
